| Literature DB >> 33790530 |
Tolcha Regasa Dago1, Dagmawit Kifle Woldemichael2, Fekede Bekele Daba3.
Abstract
BACKGROUND: Infectious keratitis is a major global cause of visual impairment and irreversible blindness among the corneal diseases. Its diagnosis and management remain getting challenge. The clinical and visual outcome remains poor in developing countries. The aim of this study was to determine treatment outcome and its predictors among patients with infectious keratitis.Entities:
Keywords: Ethiopia; infectious keratitis; microbes; risk factors; treatment outcome
Year: 2021 PMID: 33790530 PMCID: PMC7997589 DOI: 10.2147/OPTH.S291880
Source DB: PubMed Journal: Clin Ophthalmol ISSN: 1177-5467
Grade of Severity for Infectious Keratitis
| Factor | Grade I | Grade II | Grade III | Grade IV |
|---|---|---|---|---|
| Conjunctiva congestion | One quadrant congested | Two quadrant congested | Three quadrant congested | All quadrant congested |
| Corneal ulcer | 0.5–1 mm | >1–2 mm | > 2–5 mm | > 5 mm |
| Hypopyon | Up to 1 mm | >1–2 mm | >2–3 mm | > 3 mm |
| Visual acuity | 6/6–6/18 | 6/24–6/60 | < 6/60–3/60 | <3/60 |
| Corneal infiltrates | Only up to epithelial surface | Infiltrates may be dense but superficial and limited to ulcer base | Dense infiltrates extending to mid stroma | Dense infiltrates extending deeper than mid stroma or up to sclera |
| Area | 2 mm2 | 2–6 mm2 | 6–14 mm2 | >14 mm2 |
| Depth | Superficial one third | Superficial two thirds | Extending to inner one third | Involving full cornea |
Figure 1Participants enrollment at Jimma University Medical Center Ophthalmology Department from April 1 to September 30, 2019.
Sociodemographic Characteristics of Study Participants Among at JUMCOD from April to September 2019 (n=131)
| Sociodemographic Characteristics | n (%) | |
|---|---|---|
| Age (years) | 39.38±18.901 (mean ±SD) | |
| 15–24 | 34 (26) | |
| 25–44 | 41 (31.3) | |
| 44–60 | 36 (0.5) | |
| >60 | 20 (15.3) | |
| Sex (gender) | Male | 87 (66.4) |
| Female | 44 (33.6) | |
| Marital status | Married | 91 (69.5) |
| Single | 30 (22.9) | |
| Widowed/divorced | 10 (7.6) | |
| Address of participants | Rural | 89 (67.9) |
| Urban | 42 (32.1) | |
| Occupational status | Indoor | 67 (51.1) |
| Farm workers | 64 (48.9) | |
| Educational status | No formal education | 35 (26.7) |
| Read and write | 17 (13) | |
| 1–8 | 52 (39.7) | |
| 9–12 | 17 (13) | |
| College and above | 10 (7.6) | |
| Distance from hospital by car (h or km) | 0–0.5 h (5 km) | 21 (16) |
| >0.5 h (5 km) | 110 (84) | |
Abbreviation: JUMCOD, Jimma University Medical Center Ophthalmology Department.
Historical Characteristics of Study Participants at JUMCOD During April to September 2019
| Historical Characteristics | Frequency | % | |
|---|---|---|---|
| Other health-care visit before admission | Government hospital | 48 | 36.6 |
| Health center | 39 | 29.8 | |
| Private hospital | 5 | 3.8 | |
| Private clinic | 9 | 6.9 | |
| Private pharmacy | 18 | 13.7 | |
| Ocular trauma | Wooden stick | 25 | 19.1 |
| Vegetative material | 24 | 18.3 | |
| Finger nail, ash powder, object or stone | 21 | 16.0 | |
| Others | 9 | 6.9 | |
| Previous ocular disease | Previous surgical procedurea | 13 | 9.9 |
| Previous epithelial defect secondary to VK | 19 | 14.5 | |
| Glaucoma | 6 | 4.6 | |
| Dry eye | 7 | 5.3 | |
| Blepharitis and allergic conjunctivitis | 5 | 3.8 | |
| Others | 3 | 2.3 | |
| Systemic condition | Steroid use | 88 | 67.2 |
| Cancer | 2 | 1.5 | |
| HIV | 2 | 1.5 | |
| DM | 1 | 0.8 | |
| Renal failure | 2 | 1.5 | |
| Leprosy | 1 | 0.8 | |
| Adrenal insufficiency | 1 | 0.8 | |
| Traditional medicine use | Herbal medicine | 45 | 34.4 |
| Topical antibiotic use | Ciprofloxacilline 0.3% eye drops | 26 | 19.8 |
| Tetracycline 1% eye ointment | 49 | 37.4 | |
| Ciprofloxacilline and TTC | 22 | 16.8 | |
| Ciprofloxacilline and gentamicin | 5 | 3.8 | |
| Gentamicin 0.3% eye drops | 7 | 5.3 | |
| Chloramphenicol eye drops | 8 | 6.1 | |
| Others | 3 | 2.3 | |
| Use of eye glass | 12 | 9.2 | |
| Time of presentation to JUMC (mean ±SD)=27.5±21.9 days (4–99) | |||
Note: aLens changed, for one patient, cataract surgery, for two patients, repairing of trauma for eight patients, trabeculotomy one patient, repaired keratoplasty one patient.
Abbreviations: VK, viral keratitis; DM, diabetes mellitus; TTC, tetracycline.
Characteristics of Ulcer at Admission and Other Objectively Measured Clinical Feature During April to September 2019 (n=131)
| Clinical Features (Obtained on Physical Exam) | Frequency | % | |
|---|---|---|---|
| Location of epithelial defect (ulcer) | Central | 57 | 43.5 |
| Paracentral | 27 | 20.6 | |
| Periphery | 29 | 22.1 | |
| Nearly total and total | 18 | 13.7 | |
| Ulcer depth | 1/3 | 37 | 28.2 |
| >1/3 | 94 | 71.8 | |
| Infiltrate occurred | No infiltrate | 13 | 9.9 |
| Grade IV | 81 | 61.8 | |
| Grade III | 9 | 6.9 | |
| Grade II | 23 | 17.6 | |
| Grade I | 5 | 3.8 | |
| Thinning or perforation of the cornea at admission | Yes | 45 | 34.4 |
| Is hypopyon present at admission? | Yes | 40 | 30.5 |
| Ulcer size along larger axis | Mean ±SD | 5.2±2.7 mm | |
| Ulcer size along minor axis | Mean ±SD | 3.9±2.5 mm | |
| Ulcer area | Mean ±SD | 25.7±31.0 mm2 | |
Key Laboratory and Instrumental Diagnostic Used Among Study Participants at JUMCOD During April to September 2019
| Types of Laboratory and Instrumental Investigations | Result | n |
|---|---|---|
| Ophthalmic ultrasound and CT scan* | Normal study | 5 |
| Abnormal (perforation, endophthalmitis, and corneal opacity) | 15 | |
| KOH mount and gram stain | Gram-positive cocci and fungal hyphae | 2 |
| Only gram-positive cocci | 3 | |
| Only fungal hyphae seen | 5 | |
| No organism seen | 14 | |
| Culture | Positive culture and pure bacterial growth | 3 |
| Mixed bacterial and fungal growth | 1 | |
| Positive culture and fungal growth | 2 | |
| Negative | 20 | |
| CBC count | Increased WBC and neutrophil | 5 |
| Normal WBC and increased leukocyte/normal | 2 | |
| RF | One positive and one negative | 2 |
| PICT | Positive | 2 |
| RBS | For diabetes test one suggestive other not | 2 |
Note: *CT scan was only done for one patient and the result was central neuronal necrosis with vitreous floating echo.
Abbreviations: CBC, complete blood count; CT, computed tomography; RF, rheumatoid factor; PICT, provided initiative counseling test; RBS, random blood sugar; KOH, potassium hydro-oxide.
Drug Susceptibility Test for Isolated Organism Among Study Participants at JUMCOD from April to September 2019
| Species | Ampicillin | Ampicillin-sulbactam | Amoxicillin-clavulanic Acid | Tetracycline | Cefepime | Ceftriaxone | Ceftazidime | Chloramphenicol | Ciprofloxacilline | Erythromycin | Gentamicin | Meropenem | Tobramycin | Imipenem | Piperacillin-tazobactum | Cotrimoxazole |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R | S | R | S | S | S | S | S | |||||||||
| R | S | R | R | I | R | I | ||||||||||
| 2 | R | R | S | I and S | S | I and R | S | S and R | S | S | S | R |
Abbreviations: R, resistant; I, intermediate; S, susceptible.
Figure 2Ocular coorbid disease that were occurred on infectious keratitis patients at JUMCOD from April to September 2019.
Treatment for Infectious Keratitis Patients at JUMCOD from April to September 2019
| Treatment | Frequency | % |
|---|---|---|
| Fortified vancomycin eye drops 50 mg/mL (5%) and fortified gentamicin eye drops: 14 mg/mL (1.4%) | 110 | 84.0 |
| Vancomycin fortified eye drops 50 mg/mL (5%) and fortified ceftazidime eye drops 50 mg/mL | 21 | 16.0 |
| Fluconazole 0.3% eye drops | 23 | 100 |
| Fluconazole 200 mg po | 16 | 69.6 |
| Acyclovir 3% eye ointment | 61 | 100 |
| Acyclovir 200 mg or 400 mg po | 53 | 86.9 |
| TTC 1% eye ointment | 131 | 100 |
| Ciprofloxacin eye drops 0.3% | 97 | 74.0 |
| Chloramphenicol 0.3% eye drops | 13 | 9.9 |
| Others | 2 | 1.5 |
| Ceftazidime and vancomycin 0.1% intravitreal injection | 14 | 10.7 |
| Cloxacillin, ceftriaxone, and metronidazole injection | 5 | 3.8 |
| Tropic amide 0.3% | 123 | 93.9 |
| Acetazolamide 250 mg po | 47 | 35.9 |
| Ibuprofen 400 mg po | 45 | 34.4 |
| Diclofenac injection | 7 | 5.3 |
| Diclofenac eye drops | 4 | 3.1 |
| Tramadol 50 mg po | 9 | 6.9 |
| Natural tear eye drops | 21 | 16.0 |
| Glycerol | 1 | 0.8 |
Treatment Outcome of Patients Among Study Participants from April to September 2019 at JUMCOD (n=131)
| Types of Outcome | Descriptions of Treatment Outcome | n | % | |
|---|---|---|---|---|
| Primary outcome | Ulcer completely healed within 21 days (good outcome) | 48 | 36.6 | |
| Ulcer not healed within 21 days (poor outcome) | 83 | 63.4 | ||
| Secondary outcomes | Visual outcome | Visual acuity improved from baseline (good outcome) | 42 | 32.1 |
| Visual acuity remained on baseline | 18 | 13.7 | ||
| Visual acuity worsened from baseline (poor outcome) | 71 | 54.2 | ||
| Complications | Perforation | 19 | 14.5 | |
| Endophthalmitis | 10 | 8 | ||
| Corneal opacity | 9 | 7 | ||
| Uveitis | 7 | 5 | ||
| Corneal central scar within 21 days | 8 | 6 | ||
| Panophtalmitis | 5 | 4 | ||
| Descemetocele | 3 | 2 | ||
| Anterior staphyloma | 3 | 2 | ||
| Band keratopathy | 1 | 1 | ||
| Length of hospital stay mean ±SD | 17.38±12.6 days and nine patients were readmitted | |||
Figure 3Surgical treatments for infectious keratitis attending JUMCOD from April to September 2019.
Figure 4Visual outcome at different time among study participants at JUMCOD from April to September 2019.
Predictors of Poor Treatment Outcome from April to September 2019
| Variables in Multi-logistic Regression | Outcomes | COR (95%CI) | AOR (95%CI) | |||
|---|---|---|---|---|---|---|
| Good (%) | Poor (%) | |||||
| Occupation | Indoor | 31 (23.7) | 36 (27.5) | |||
| Farm worker | 17 (13.0) | 47 (35.9) | 2.4 (1.1–5) | 0.035* | 3.6 (1.1–11.8) | |
| Systemic condition | Yes | 29 (22.1) | 67 (51.1) | 2.7 (1.2–6.1) | 0.078 | 3.2 (0.9–12) |
| No | 19 (14.5) | 16 (12.2) | ||||
| Ulcer depth | ≤1/3 | 27 (20.6) | 10 (7.6) | |||
| >1/3 | 21 (16.03) | 73 (55.7) | 9.4 (3.9–22.5) | <0.001* | 7.6 (2.5–23.5) | |
| Traditional medicine use | Yes | 7 (5.3) | 38 (29.0) | 4.9 (2–12.3) | 0.005* | 6.7 (1.8–25.4) |
| No | 41 (31.3) | 45 (34.4) | ||||
| Adherence | Poor | 3 (2.3) | 32 (24.4) | 9.4 (2.7–32.8) | 0.042* | 5.254 (1.066–25.9) |
| Good | 45 (34.4) | 51 (38.9) | ||||
| Comorbid occurred | Yes | 10 (7.6) | 40 (30.5) | 3.5 (1.6–8) | 0.002* | 7.7 (2.2–27.3) |
| No | 38 (29.0) | 43 (32.8) | ||||
| Thinning or perforation at admission | Yes | 5 (3.8) | 40 (30.5) | 8 (2.9–22) | 0.012* | 6.125 (1.5–25.1) |
| No | 43 (32.8) | 43 (32.8) | ||||
Notes: *Significant predictor. p-value, independent predictor that has statistically significant association with poor treatment outcome was p<0.05.
Abbreviations: AOR, adjusted odds ratio; COR, crude odds ratio.